These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12974118)

  • 1. Good news and bad news: the cost of mending a broken heart.
    Williams D
    Med Device Technol; 2003; 14(1):8-10. PubMed ID: 12974118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure.
    Technol Eval Cent Assess Program Exec Summ; 2004 Apr; 19(2):1. PubMed ID: 15314825
    [No Abstract]   [Full Text] [Related]  

  • 3. Special report: left ventricular assist devices as destination therapy for end-stage heart failure--cost-effectiveness analysis.
    TEC Bull (Online); 2003 Nov; 20(3):33-4. PubMed ID: 15043081
    [No Abstract]   [Full Text] [Related]  

  • 4. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era.
    Miller LW; Nelson KE; Bostic RR; Tong K; Slaughter MS; Long JW
    J Heart Lung Transplant; 2006 Jul; 25(7):778-84. PubMed ID: 16818120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The technological imperative and the battle for the hearts of America.
    Gillick MR
    Perspect Biol Med; 2007; 50(2):276-94. PubMed ID: 17468543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular assist devices as alternative to heart transplant. When will they replace allogenic heart transplants?
    Busund R
    Scand Cardiovasc J; 2002 Dec; 36(6):323-6. PubMed ID: 12626196
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanical devices and US Food and Drug Administration (FDA) approval.
    Reitz BA
    Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu; 2006; ():123-7. PubMed ID: 16638557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future devices and directions.
    Clark RE; Zafirelis Z
    Prog Cardiovasc Dis; 2000; 43(1):95-100. PubMed ID: 10935561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A space age vision advances in the clinic.
    Marshall E
    Science; 2002 Feb; 295(5557):1000-1. PubMed ID: 11834810
    [No Abstract]   [Full Text] [Related]  

  • 11. Innovation with experience using implantable left ventricular assist devices.
    Ascheim DD; Gelijns AC; Rose EA
    Circ Heart Fail; 2009 Jan; 2(1):1-2. PubMed ID: 19808308
    [No Abstract]   [Full Text] [Related]  

  • 12. Costs associated with ventricular assist device use in children.
    Mahle WT; Ianucci G; Vincent RN; Kanter KR
    Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic aspects of implementation of the mechanical heart, "HeartMate"].
    Kolbye A; Sander Jensen KM; Aldershvile J; Hansen PB; Kjersem AM; Nielsen KS; Olsen PS; Rasmussen B; Vogelsang G
    Ugeskr Laeger; 2000 Jun; 162(26):3722-5. PubMed ID: 10925632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the total artificial heart.
    Gray NA; Selzman CH
    Am Heart J; 2006 Jul; 152(1):4-10. PubMed ID: 16824826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REMATCH and beyond: the cost of treating heart failure using an implantable left ventricular assist device.
    Dembitsky WP
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):253-5. PubMed ID: 16959761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Destination therapy: does progress depend on left ventricular assist device development?
    von Bayern MP; Cadeiras M; Deng MC
    Heart Fail Clin; 2007 Jul; 3(3):349-67. PubMed ID: 17723941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular assist device: can Canada afford this?
    Carrier M
    Can J Cardiol; 2005 Nov; 21(13):1166-8. PubMed ID: 16308591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left-ventricular assist devices as destination therapy for end-stage heart failure.
    TEC Bull (Online); 2002 Nov; 19(3):28-30. PubMed ID: 12839024
    [No Abstract]   [Full Text] [Related]  

  • 20. Heart transplant and left ventricular assist device costs.
    Digiorgi PL; Reel MS; Thornton B; Burton E; Naka Y; Oz MC
    J Heart Lung Transplant; 2005 Feb; 24(2):200-4. PubMed ID: 15701438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.